MedTrace Logo

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

NCT03019757 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2025-03-30

No results posted yet for this study

Summary

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

Conditions

Interventions

RADIATION

DaTscan

A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT

RADIATION

F18-AV-45

A brain scan to to measure the extent of amyloid deposition

RADIATION

FDG-PET

a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)

GENETIC

APOE genotype

10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.

PROCEDURE

Polysomnogram

Overnight sleep study

BEHAVIORAL

Clinical Assessment

Clinical assessments include cognitive, behavioral, and motor evaluations

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    collaborator INDUSTRY

  • Mangurian Foundation

    collaborator UNKNOWN

  • Douglas Scharre

    lead OTHER

Principal Investigators

  • Douglas W Scharre, MD · Ohio State University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-30
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019757 on ClinicalTrials.gov